1. Scrip

Cerulean Shifts From Ovarian Cancer To Contraceptives In Reverse Merger With Daré

 
• By Mandy Jackson

Cerulean and privately-held Daré entered into a stock purchase agreement that will give the latter company's shareholders a majority stake in the combined company, which will focus on women's health – particularly contraceptives – instead of the former firm's nanoparticle-drug conjugates for cancer.

Handshake of businessmen

Cerulean Pharma Inc. has sold the last of its assets and will flip its empty shell to Daré Bioscience Inc. during the second quarter of 2017, now that the company has given up all hope that a partner would come to the rescue after a devastating Phase II clinical trial failure last year.

Waltham, Mass.-based Cerulean will execute a reverse merger that will give shareholders of the privately held women's health firm Daré, headquartered in San Diego, Calif., a majority stake in the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Merus Bispecific Impresses In Head And Neck Cancer

 
• By Andrew McConaghie

Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.

Zydus To Continue Mirabegron Sales, Looks To World-First Dual Shigella-Typhoid Vaccine

 
• By Vibha Ravi

Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list

Challenging Environment For Biopharma Is A Tailwind For Royalty Pharma

 
• By Jessica Merrill

The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.